- TheStreet.com•16 days ago
David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.
- TheStreet.com•last month
Answering questions from the Biotech Mailbag on FLXN and SGYP.
- TheStreet.com•2 months ago
AstraZeneca shares, meanwhile, were less-than-moved by the news.
MDVN : Summary for Medivation, Inc. - Yahoo Finance